Melanoma

- IRB#11848: Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence
- IRB#15661: A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
- IRB#16883: A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection
- IRB#16198: A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides
- IRB#1687: A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic BRAF V600 mutant melanoma

Adjuvant Therapies

- IRB#11848: Stages 2B, 2C, or 3
- IRB#15661: Stages 3 or 4 resectable

Non-Mutation Specific

- IRB#1687: Stages 3 or 4, unresectable

Mutation Specific

- BRAF V600 Mutation

Please refer to Phase I studies for more clinical trial opportunities

- IRB#17104: DecisionDx-Melanoma 31 Gene Expression Profile Clinical Impact Study
- IRB#16162: A Phase I, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation
- IRB#18687: A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic BRAF V600 mutant melanoma

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

7/20/2018